CRISPRs Enlisted to Study Mutations Across an Entire Mammalian Genome
By GEN,
Genetic Engineering & Biotechnology News
| 12. 24. 2013
Scientists at the Wellcome Trust Sanger Institute have developed a technique to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types, the researchers say.
CRISPR technology uses the DNA-cutting enzyme Cas9, with the help of a guide RNA sequence, to find and modify genetic targets. Scientists engineer multiple new guide RNAs using standard molecular biology techniques. This makes for a much faster and efficient method to modify the genome of any cell type in any species, according to the Wellcome group.
The team, which published their results online (“Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library”) in Nature Biotechnology, found that 50 of 52 guide RNAs tested successfully cut both copies of the genes. The high success rate for these engineered guide RNAs seems to be consistent across many cell types, which led them to create a library of guide RNAs targeting every gene in the mouse genome.
“We designed 87,897 guide RNAs (gRNAs) targeting...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...